NCT06347458View on ClinicalTrials.gov

BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

August 31, 2027

Conditions

LeukemiaAcute Myeloid Leukemia

Interventions

BIOLOGICAL

BG1805

A single infusion of BG1805 Injection administered intravenously.

All Listed Sponsors

lead

Guangzhou Bio-gene Technology Co., Ltd

INDUSTRY